Pioglitazone News and Research

RSS

GlaxoSmithKline responds to Journal of the American Medical Association articles

GlaxoSmithKline believes that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. and Furberg et. al. in the Journal of the American Medical Association do not confirm a difference in the safety profile of Avandia (rosiglitazone) and Actos (pioglitazone).

12 Sep 2007

Diabetes drug Pioglitazone reduces risk of death, heart attack and stroke, but increases risk of heart failure

A drug widely used to treat type 2 diabetes has been found to reduce the risk of death, heart attack (myocardial infarction) or stroke when used alone or in combination with other therapies for diabetes, according to a Cleveland Clinic study.

12 Sep 2007

Strengthened warnings on some type 2 diabetes drugs

The U.S. Food and Drug Administration has announced manufacturers of certain drugs approved to treat Type 2 diabetes have agreed to add a stronger warning on the risk of heart failure, a condition that occurs when the heart does not adequately pump blood.

16 Aug 2007

FDA Avandia recommendation welcomed by Endocrinologists

The American Association of Clinical Endocrinologists (AACE), along with the rest of the medical community, has watched with concern the debate regarding usage of GlaxoSmithKline's rosiglitazone (Avandia) in diabetes and the question of whether it increases cardiovascular risk.

1 Aug 2007

Takeda responds to FDA recommendation on Actos

Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

30 Jul 2007

Avandia too risky says expert

One of the members of the advisory panel set up to discuss the future of the diabetes pill Avandia says it should be removed from the market because it is too risky and offers no advantage over other alternatives.

30 Jul 2007

Metformin gets top grade for diabetes

A type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.

26 Jul 2007

Analysis of diabetes drugs

Most oral medications prescribed for type 2 diabetes are similarly effective for reducing blood glucose, but the drug metformin is less likely to cause weight gain and may be more likely than other treatments to decrease so-called bad cholesterol, according to a report funded by HHS Agency for Healthcare Research and Quality.

17 Jul 2007

Diabetes drug rosiglitazone boosts power of platinum chemotherapy

A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, scientists from Dana-Farber Cancer Institute report.

8 May 2007

Piolitazone shows promise for preventing brain injury from radiation therapy

Researchers at Wake Forest University School of Medicine are the first to report that in animal studies, a common diabetes drug prevents the memory and learning problems that cancer patients often experience after whole-brain radiation treatments.

10 Jan 2007

Pioglitazone may help slow progression of artery wall thickening

A medication given to diabetics to improve their body's sensitivity to insulin also appears to slow the thickening of their artery walls, according to a study posted online by JAMA: The Journal of the American Medical Association.

13 Nov 2006

Thiazolidinediones may reduce cardiovascular risks

A drug commonly used to increase the body's sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes, according to a study at the University of Illinois at Chicago College of Medicine.

13 Nov 2006

Alzheimer's disease linked to raised blood sugar levels

Researchers at an Alzheimer's Conference in Spain have come up with more information on the disease and just who amongst the population is most likely to get it.

17 Jul 2006

Pioglitazone shows promise in treating Alzheimer's

Treatment of high blood sugar may have a scientific connection to memory loss that could, one day, benefit millions of people with Alzheimer's Disease, which affects up to 4.5 million older Americans, bringing with it impaired thinking and memory.

17 Jul 2006

Impact of obesity on treatment of chronic hepatitis C

According to a new study, obese patients chronically infected with the hepatitis C virus (HCV) and treated with combination drug therapy may have better outcomes if the underlying abnormalities caused by excessive fat tissue are corrected.

6 Jun 2006

Latest diabetic medications more costly, but users have fewer hospital visits

Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades.

22 Mar 2006

Study reveals mechanisms behind Thiazolidinediones used to treat type 2 diabetes

Thiazolidinediones (TZD's) are drugs commonly prescribed to patients with type 2 diabetes, the most common form of diabetes. Current U.S. Food and Drug Administration-approved agents are known as Actos (pioglitazone) and Avandia (rosiglitazone).

13 Mar 2006

Takeda wins patent infringement case

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc. have announced that Takeda's intellectual property rights have been successfully asserted against generic manufacturers seeking to challenge Takeda's patent rights to ACTOS (pioglitazone HCl).

24 Feb 2006

New device to detect early signs of heart conditions

A Yorkshire heart-monitor company is one of five technology businesses hoping to raise finance at the White Rose Bioscience Forum, Yorkshire’s flagship bioscience event - in York today (01 November 2005).

1 Nov 2005

Actos reduces the combined risk of non-fatal heart attacks, strokes in patients with type-2 diabetes

A study published in The Lancet shows that Takeda's Actos (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk of non-fatal heart attacks, strokes and deaths by an additional 16% on top of standard medication

10 Oct 2005